Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Edi Schuepbach"'
Autor:
Dorothee Abramowski, Hugo Bürki, Edi Schuepbach, Daniel Hoyer, Thomas Dürst, Géraldine M. Mang, Christine E. Gee, Markus Fendt, Stefan Imobersteg
Publikováno v:
Sleep. 35:1625-1635
Study Objectives: Orexin peptides activate orexin 1 and orexin 2 receptors (OX1R and OX2R), regulate locomotion and sleep-wake. The dual OX1R/OX2R antagonist almorexant reduces activity and promotes sleep in multiple species, including man. The relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eef137a6c467aff3bce1d6018756c32a
https://doi.org/10.5665/sleep.2232
https://doi.org/10.5665/sleep.2232
Autor:
Dominique Fehlmann, Edi Schuepbach, Daniel Langenegger, Caroline Nunn, Davide Cervia, Daniel Hoyer
Publikováno v:
British Journal of Pharmacology. 139:109-121
The mouse corticotroph tumour cell line AtT-20 is a useful model to investigate the physiological role of native somatostatin (SRIF, Somatotropin release inhibitory factor) receptor subtypes (sst1 – sst5). The objective of this study was to charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cb92ea51c9455271845901cd08a4bd6
https://doi.org/10.1038/sj.bjp.0705235
https://doi.org/10.1038/sj.bjp.0705235
Autor:
Carla Biondi, Philippe Zizzari, Edi Schuepbach, Jacques Epelbaum, Paola Bagnoli, Davide Cervia, Daniel Langenegger, Barbara Pavan, Daniel Hoyer
Publikováno v:
Neuropharmacology. 44:672-685
The physiological actions of somatostatin-14 (SRIF: somatotrophin release inhibitory factor) receptor subtypes (sst(1)-sst(5)), which are endogenously expressed in growth cells (GC cells), have not yet been elucidated, although there is evidence that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f568062c380ddb3290669ac2f0fe7708
https://doi.org/10.1016/s0028-3908(03)00031-5
https://doi.org/10.1016/s0028-3908(03)00031-5
Autor:
Edi Schuepbach, Konstanze Hurth, Thierry Kimmerlin, Daniel Langenegger, Caroline Nunn, Dieter Seebach, Peter Micuch, Magnus Rueping, Daniel Hoyer
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 367:95-103
Four linear β2/β3-di- and α/β3-tetrapeptides (1–4) were investigated as somatostatin sst4 receptor agonists on recombinant human and mouse somatostatin receptors. Human somatostatin receptor subtypes 1–5 (sst1–5), and mouse somatostatin rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aca6761422bd168a468b91aabf16beb9
https://doi.org/10.1007/s00210-002-0673-4
https://doi.org/10.1007/s00210-002-0673-4
Autor:
Silvio Ofner, Dirk Behnke, Edi Schuepbach, Christine E. Gee, Morenike Olorunda, Samuel Hintermann, Markus Fendt, Emmanuelle Briard, Daniel Langenegger, Daniel Hoyer, Grit Laue, Gabrielle E. Callander, Laura H. Jacobson, Claudia Betschart, Simona Cotesta, Dominique Monna
Publikováno v:
Frontiers in Neuroscience
Orexin receptor antagonists represent attractive targets for the development of drugs for the treatment of insomnia. Both efficacy and safety are crucial in clinical settings and thorough investigations of pharmacokinetics and pharmacodynamics can pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c48587021d06fac0335b5334a7b2ec
Autor:
Daniel Langenegger, Edi Schuepbach, Maurizio Cammalleri, Philippe Schoeffter, Daniel Hoyer, Herbert A. Schmid, Paola Bagnoli, Davide Cervia
Publikováno v:
Neuropharmacology. 48(6)
Clinically used somatostatin (SRIF) analogs octreotide and lanreotide act primarily by binding to SRIF receptor subtype 2 (sst2). In contrast, the recently described multiligand SOM230 binds with high affinity to sst1-3 and sst5 and KE 108 is charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd5109e11d011454efc53e41aed837b6
https://pubmed.ncbi.nlm.nih.gov/15829258
https://pubmed.ncbi.nlm.nih.gov/15829258
Autor:
Edi Schuepbach, Jason P. Hannon, Rochdi Bouhelal, Daniel Hoyer, Troxler Thomas J, P. Pfaeffli, Neumann Peter, Caroline Nunn, Daniel Langenegger, Konstanze Hurth, Philippe Schoeffter, Dominik Feuerbach
Publikováno v:
Neuroscience letters. 361(1-3)
This report describes the in vitro features of the first somatostatin sst 1 receptor selective non-peptide antagonist, SRA880 ([3R,4aR,10aR]-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g] quinoline-3-carboxylic-acid-4-(4-nitro-phenyl)-piper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe516e2e869b9179c6e65844ddca1ded
https://pubmed.ncbi.nlm.nih.gov/15135911
https://pubmed.ncbi.nlm.nih.gov/15135911
Autor:
Davide, Cervia, Caroline, Nunn, Dominique, Fehlmann, Daniel, Langenegger, Edi, Schuepbach, Daniel, Hoyer
Publikováno v:
British journal of pharmacology. 139(1)
1. The mouse corticotroph tumour cell line AtT-20 is a useful model to investigate the physiological role of native somatostatin (SRIF, Somatotropin release inhibitory factor) receptor subtypes (sst(1) - sst(5)). The objective of this study was to ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::25414ba2bf5dd0741fa35f18d5b631d9
https://pubmed.ncbi.nlm.nih.gov/12746229
https://pubmed.ncbi.nlm.nih.gov/12746229
Autor:
Caroline, Nunn, Magnus, Rueping, Daniel, Langenegger, Edi, Schuepbach, Thierry, Kimmerlin, Peter, Micuch, Konstanze, Hurth, Dieter, Seebach, Daniel, Hoyer
Publikováno v:
Naunyn-Schmiedeberg's archives of pharmacology. 367(2)
Four linear beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptides (1-4) were investigated as somatostatin sst(4) receptor agonists on recombinant human and mouse somatostatin receptors. Human somatostatin receptor subtypes 1-5 (sst(1-5)), and mouse som
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ecb25e270a0ad810fde6746a0eaa333
https://pubmed.ncbi.nlm.nih.gov/12595949
https://pubmed.ncbi.nlm.nih.gov/12595949